Status:

COMPLETED

Genetics and Pain Severity in Sickle Cell Disease

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Genotype

Pain

Eligibility:

All Genders

18-99 years

Brief Summary

Background: \- Pain is the most common symptom of sickle cell disease. Episodes of severe sickle cell pain are known as "crises." High rates of pain crises are associated with a higher risk of early ...

Detailed Description

Sickle cell disease (SCD) is the most common genetic disease in the United States inherited as an autosomal recessive disorder, where approximately 70,000 individuals have sickle cell disease. Acute p...

Eligibility Criteria

Inclusion

  • ELIGIBILITY CRITERIA FOR ALL PARTICIPANTS:
  • All study participants must be of self-described African or African American ancestry. They will be at least 18 years old and must be able to provide informed, written consent for participation.
  • INCLUSION CRITERIA:
  • Inclusion Criteria for Sickle Cell Patients
  • Diagnosis of sickle cell disease (documentation of SS, SC, S beta + thalassemia, S beta + thalassemia by electrophoresis is required).
  • If taking chronic analgesics (NSAID, acetaminophen) or opioids, study subjects should be on a stable dose for 4 weeks prior to recruitment.
  • Inclusion Criteria for Control Subjects
  • Hemoglobin AA genotype by HPLC or hemoglobin electrophoresis.
  • General good health defined as the absence of untreated major medical conditions (e.g. uncontrolled systemic hypertension, etc.).
  • EXCLUSION CRITERIA:
  • Exclusion Criteria for Sickle Cell Patients
  • History of severe vaso-occlusive pain crisis resulting in either evaluation in an emergency department or admission to a hospital during the two weeks prior to study enrollment.
  • Acute pain at the time of enrollment defined as spontaneous recent onset pain with a self rated score of 6 or higher on a scale of 0-10. (This is acute pain not the pain that subjects function at on a daily basis.)
  • Exclusion Criteria for Control Subjects
  • Acute pain or injury at enrollment or a recent history of chronic pain (daily pain reported for at least 6 months) in the past 3 years.
  • Major medical/psychiatric illness known to cause pain.
  • Sickle cell trait.

Exclusion

    Key Trial Info

    Start Date :

    June 17 2012

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 9 2020

    Estimated Enrollment :

    67 Patients enrolled

    Trial Details

    Trial ID

    NCT01441141

    Start Date

    June 17 2012

    End Date

    December 9 2020

    Last Update

    December 10 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892